Physician profile
Dexter Sun
NPI 1508066705
$12,155.04
in general payments reported to CMS, 2019-2025
42 companies · $2,392 in 2025
The $2,392 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,831 · 2020: $758 · 2021: $1,382 · 2022: $1,695 · 2023: $1,944 · 2024: $2,153 · 2025: $2,392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,489.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,489.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,926.72 | 2021-2025 | Qulipta, Ubrelvy |
| Lundbeck LLC | $1,018.76 | 2019-2025 | Rexulti, Vyepti |
| Biogen, INC. | $810.09 | 2019-2025 | Leqembi, Tysabri, Vumerity |
| Lilly USA, LLC | $697.62 | 2019-2025 | Kisunla, Amyvid |
| Ucb, INC. | $583.39 | 2019-2025 | Rystiggo |
| Emd Serono, INC. | $561.62 | 2022-2025 | Mavenclad |
| Pfizer INC. | $551.48 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $454.08 | 2019-2024 | Austedo Xr, Austedo, Ajovy |
| Grifols USA, LLC | $436.34 | 2019-2025 | Gamunex-C |
| Otsuka America Pharmaceutical, INC. | $400.73 | 2023-2025 | Rexulti, Nuedexta |
| Eisai INC. | $346.49 | 2023-2025 | |
| Tg Therapeutics, INC. | $331.33 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $291.98 | 2019-2024 | |
| Genzyme Corporation | $283.34 | 2019-2023 | |
| Allergan, INC. | $277.36 | 2019-2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dexter Sun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.